[Company letterhead]
[Date]
Office of Inspector General, [Department of War / agency] [Contractor Disclosure Program address]
cc: Contracting Officer, [contract numbers]; Administrative Contracting Officer; DCAA [office]
Re: Disclosure under FAR 52.203-13 [or voluntary disclosure] concerning independent research and development costs relating to unidentified anomalous phenomena
Dear [IG]:
[Company] submits this [disclosure / voluntary disclosure] concerning the treatment of certain independent research and development (“IRAD”) costs.
1. Background. Section 1687(b) of the National Defense Authorization Act for Fiscal Year 2024, Pub. L. No. 118-31 (50 U.S.C. §3373 note), provides that “independent research and development funding relating to unidentified anomalous phenomena shall not be allowable as indirect expenses for purposes of contracts covered by [DoD Instruction 3204.01], unless such material and information is made available [to] the appropriate congressional committees and congressional leadership.”
2. Facts. [Describe, at an unclassified level, the IRAD project(s), the periods, the cost pools, the amounts included in indirect cost submissions, and whether and when material and information were made available to the committees and congressional leadership. Identify any classified addendum delivered through security channels.]
3. Assessment. [Company] has determined that [amount] in IRAD costs incurred from [date] to [date] may not have satisfied the condition in §1687(b) at the time they were included in [indirect cost rate proposals / billings]. [Company] [does / does not] believe the circumstances amount to credible evidence of a violation of the civil False Claims Act; it makes this disclosure [in compliance with FAR 52.203-13(b)(3)(i) / in the interest of transparency].
4. Corrective action. [Company] has (a) removed the costs from [pools/proposals]; (b) calculated the effect on billings at [amount] and proposes [credit/refund]; (c) [made / arranged to make] the material and information available to the appropriate committees and congressional leadership on [date]; (d) adopted procedures to identify UAP-related IRAD; and (e) preserved all related records, including records subject to FY2024 NDAA §1842.
5. Employee protections. [Company] has advised its employees of their right to make authorized disclosures to the All-domain Anomaly Resolution Office under 50 U.S.C. §3373b and of the prohibition on reprisal.
6. Contact. [Name, title, contact.]
Sincerely, [Authorized officer]